Dr. Karim Fizazi, medical oncologist at the Institut Gustave Roussy at Villejuif, discussed the outcomes of the TALAPRO-2 study, evaluating the combination of talazoparib and enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer harbouring homologous recombination repair gene alterations. He concluded with an overview of the role of PARP inhibitors in prostate cancer.
With the educational support of:
